When does the secukinumab patent expire?
Secukinumab (marketed as Cosentyx) has patent protections tied to specific jurisdictions, formulations, and manufacturing processes, so the exact “expiry date” depends on the country and the particular patent family being counted. Patent-watch sources track this by jurisdiction and publication/patent number rather than a single global end date.
For a jurisdiction-focused view of the patent landscape for secukinumab, see DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/ (search for “secukinumab” on the site). [1]
What patents protect secukinumab (Cosentyx)—active ingredient or formulations?
Secukinumab protections typically include multiple layers, such as patents on the biologic itself (composition/claims around the molecule) and follow-on patents covering things like manufacturing, formulations, and related dosing/device aspects. That means even after one patent family ends, other patent families (or related litigation) can extend market exclusivity in some countries. [1]
Are there bio-biosimilar entry risks before all patents expire?
Yes. Biosimilar developers often challenge whether specific patents are valid and/or infringed (so-called patent litigation or “carve-outs” depending on the country’s rules). In practice, that can delay launch even if the biologic’s main market exclusivity is approaching, because ongoing disputes can block entry until courts or settlements resolve them. [1]
Who’s competing with secukinumab, and how does that connect to patents?
Biosimilar competition is usually the main “why now” behind patent work for biologics like secukinumab. Patent-watch tracking helps identify which companies filed around which patent families, and which ones are likely to matter for launch timing (again, by jurisdiction). [1]
What should you check if you need the “real” expiry date for a specific market?
If you’re looking for an actionable date (for planning, investing, or research), you usually need:
1) the country (US, EP countries, UK, etc.),
2) the patent family/patent numbers you care about, and
3) the relevant protection type (basic patent vs. follow-on vs. exclusivity/litigation status).
DrugPatentWatch.com is designed to support that kind of targeted lookup for secukinumab. [1]
DrugPatentWatch.com source
[1] https://www.drugpatentwatch.com/patent/ (search for “secukinumab” on the site)
If you tell me the country (for example, US vs. EU vs. UK) and whether you mean “patent expiry” or “market exclusivity,” I can help you narrow down which specific secukinumab patents typically drive launch timing in that market.